DRKS00016344已完成未知
Evaluation of novel topical niacin nutriceuticals for improving gut microbiota and metabolic health
niversitätsklinikum Schleswig-Holstein0 个研究点目标入组 30 人开始时间: 2019年1月8日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomized controlled study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 19 Years 至 65 Years（—）
- 性别
- All
入选标准
- •Non-Smokers betweenn 19 and 65 years with normal liver- and kidney function.
排除标准
- •Exclusion criteria are pregnancy, rheumatic or infectiological diseases (e.g. rheumatism or chronic viral hepatitis), drug use, excessive consumption of alcohol, intake of supplements (e.g. multivitmain or trace elements) and intake of protein shakes (e.g. Almased and BCM).
- •[Further, probands should not take any medication (exception: birth control pill or thyroid hormones)].
研究者
相似试验
尚未招募
2 期
Topical niacinamide in graded concentrations on skin health metrics in Indian womeCTRI/2024/02/063151asons India Pvt. Ltd.
招募中
Unknown
The benefit of Nicotinamide + Vitamin C + Hyaluronic Acid, compared to Hydroquinone in the treatment of MelasmaMelasmaL989RBR-4mkfmr8Faculdade de Medicina de Botucatu, Universidade Estadual Paulista
招募中
2 期
evaluation of topical niosomal zinc sulphate in leishmaniasisAcute cutaneous leishmaniaisis.Cutaneous leishmaniasisIRCT20170806035524N4Kerman University of Medical Sciences64
Unknown
4 期
Effectiveness of Topical Niacinamide, Zinc and Magnesium combined with Doxycycline in the treatment of Acne Vulgaris in Thai femaleModerate to severe Acne Vulgaris in Thai femaleAcne VulgarisTCTR20230120002Ornicha Perapapan30
进行中（未招募）
1 期
Evaluation of the effect of NICOtinic acid (niacin) on elevated Lipoprotein(a) levels (NICOLa Study) - NICOLaipoprotein (Lp)(a) has been associated with an increased risk of coronary heart disease, cerebrovascular disease, and peripheral arterial vascular disease. Potential therapies to reduce elevated Lp(a) levels include nicotinic acid (niacin), but there is a lack of randomised controlled studies assessing the effectiveness of these therapies in lowering Lp(a) as a primary endpoint and in reducing cardiovascular events in the long term.EUCTR2006-005710-12-DECharité Universitätsmedizin Berlin150